🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. Ipilimumab, OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab

    The George Institute

    Adjuvant therapy after salvage surgery of high risk recurrent head and neck squamous cell carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  2. Istaroxime

    WINDTREE THERAPEUTICS INC /DE/

    Cardiogenic Shock

    phase 2 small molecule active

    2 trials

  3. Istaroxime, LActose

    WINDTREE THERAPEUTICS INC /DE/

    Cardiogenic Shock

    phase 2 small molecule active

    1 trial

  4. Itepekimab (SAR440340)

    Regeneron UK Limited

    Chronic Rhinosinusitis Without Nasal Polyps

    phase 2 small molecule active

    1 trial

  5. Itepekimab (SAR440340)

    Regeneron UK Limited

    Bronchiectasis

    phase 2 small molecule completed

    1 trial

  6. Ivonescimab

    Summit Therapeutics

    Stomach Cancer Stage IV

    phase 2 small molecule active

    1 trial

  7. Ivonescimab

    Summit Therapeutics

    Metastatic Esophageal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  8. Ivonescimab 10 mg/kg

    Summit Therapeutics

    Extensive Stage Lung Small Cell Cancer

    phase 2 small molecule active

    1 trial

  9. Ivonescimab 20 mg/kg

    Hospital Authority, Hong Kong

    Nasopharyngeal Carcinoma (NPC)

    phase 2 small molecule active

    1 trial

  10. JCAR017

    Celgene Europe Limited

    Lymphoma, Non-Hodgkin

    phase 2 small molecule completed

    1 trial

  11. JEMPERLI 500 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    Cervical cancer

    phase 2 small molecule active

    1 trial

  12. JEMPERLI 500 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    MMRd/MSI-H stage II-III endometrial cancer

    phase 2 small molecule active

    1 trial

  13. JEMPERLI 500 mg concentrate for solution for infusion, Zejula 100 mg film-coated tablets

    The George Institute

    DNA repair-deficient or platinum-sensitive solid tumors

    phase 2 small molecule active

    1 trial

  14. JNJ-42756493, JNJ-42756493, JNJ-42756493

    Janssen-Cilag International N.V.

    Advanced solid tumors (other than Urothelial tumors), and FGFR gene alterations.

    phase 2 small molecule active

    1 trial

  15. JNJ-73841937, JNJ-61186372, Zirabev 25 mg/ml concentrate for solution for infusion.

    Partner Therapeutics Limited

    Patients with EGFR-mutant (L858R or del19 only) advanced non-squamous NSCLC, who have progressed on previous treatment with a third-generation EGFR-TKI.

    phase 2 small molecule active

    1 trial

  16. JNJ-95475939, Placebo JNJ-95475939, Dupixent 300 mg solution for injection in pre-filled syringe

    Janssen-Cilag International N.V.

    Moderate to Severe Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  17. JS004

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Limited Stage Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  18. KB105

    Krystal Biotech Netherlands B.V.

    TGM-1 Related Autosomal Recessive Congenital Ichthyosis

    phase 2 mab active

    1 trial

  19. KB304

    Krystal Biotech Netherlands B.V.

    Wrinkles in Decolletage

    phase 2 mab active

    1 trial

  20. KETOROLAC, PREGABALIN

    The George Institute

    Estrogen receptor-positive early breast cancer (ER + BC).

    phase 2 small molecule active

    1 trial

  21. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Relapsed or refractory Classical Hodgkins Lymphoma and relapsed or refractory Primary Mediastinal Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  22. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Acasunlimab

    Genmab A/S

    Malignant Solid Tumors - Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  23. KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATIN , GEMCITABINE , PACLITAXEL , FAMOTIDINE , MK-2870, PARACETAMOL , CISPLATIN , PEMETREXED , -, -

    Merck Sharp and Dohme

    Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  24. KEYTRUDA 25 mg/mL concentrate for solution for infusion, ENDOXAN 1000 mg, poudre pour solution injectable, EPIRUBICINE MEDAC 2 mg/ml, solution pour perfusion, PACLITAXEL KABI 6 mg/ml, solution à diluer pour perfusion.

    The George Institute

    Breast cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources